Entrada Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 158.65M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Details
| Name | Entrada Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 152 |
| Founded | 2016 |
| Ipo Date | 2021-10-29 |
| Ceo | Dipal Doshi |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 20.00 |
| Isin | US29384C1080 |
| Cusip | 29384C108 |
| Cik | 1689375 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dipal Doshi | Chief Executive Officer and Director |
| Nathan J. Dowden | President and Chief Operating Officer |
| Dr. Natarajan Sethuraman Ph.D. | President of Research and Development |
| Kory James Wentworth CPA | Chief Financial Officer and Treasurer |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel |
Contact
| Address | One Design Center Place, Suite 17- 500, Boston, Massachusetts 02210, United States |
| Phone | 857 520 9158 |
| Website | https://www.entradatx.com |